Cover Image
市場調查報告書

Virobay Inc. : 產品平台分析

Virobay Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192873
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Virobay Inc. : 產品平台分析 Virobay Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 33 Pages
簡介

Virobay Inc.是開發、商品化劃時代藥劑之臨床階段製藥公司。該公司的多元化藥物候補配合的是神經痛和自體免疫疾病,肝纖維化,癌症等治療領域。

本報告提供Virobay Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Virobay Inc.的基本資料

  • Virobay Inc.概要
  • 主要資訊
  • 企業資料

Virobay Inc.:R&D概要

  • 主要的治療範圍

Virobay Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Virobay Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 第0相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Virobay Inc.:藥物簡介

  • VBY-036
  • VBY-129
  • VBY-376
  • VBY-285
  • VBY-825
  • VBY-50365
  • VBY-X
  • Small Molecule to Inhibit Cathepsin Protease for Cancer

Virobay Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Virobay Inc.:最近的開發平台趨勢

Virobay Inc.:暫停中的計劃

Virobay Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07432CDB

Summary

Global Markets Direct's, 'Virobay Inc. - Product Pipeline Review - 2015', provides an overview of the Virobay Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Virobay Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Virobay Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Virobay Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Virobay Inc.'s pipeline products

Reasons to buy

  • Evaluate Virobay Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Virobay Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Virobay Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Virobay Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Virobay Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Virobay Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Virobay Inc. Snapshot
    • Virobay Inc. Overview
    • Key Information
    • Key Facts
  • Virobay Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Virobay Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Virobay Inc. - Pipeline Products Glance
    • Virobay Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
      • Phase 0 Products/Combination Treatment Modalities
    • Virobay Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Virobay Inc. - Drug Profiles
    • VBY-036
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-129
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-376
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-285
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-825
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-50365
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-X
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Cathepsin Protease for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Virobay Inc. - Pipeline Analysis
    • Virobay Inc. - Pipeline Products by Target
    • Virobay Inc. - Pipeline Products by Route of Administration
    • Virobay Inc. - Pipeline Products by Molecule Type
    • Virobay Inc. - Pipeline Products by Mechanism of Action
  • Virobay Inc. - Recent Pipeline Updates
  • Virobay Inc. - Dormant Projects
  • Virobay Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Virobay Inc., Key Information
  • Virobay Inc., Key Facts
  • Virobay Inc. - Pipeline by Indication, 2015
  • Virobay Inc. - Pipeline by Stage of Development, 2015
  • Virobay Inc. - Monotherapy Products in Pipeline, 2015
  • Virobay Inc. - Out-Licensed Products in Pipeline, 2015
  • Virobay Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Virobay Inc. - Phase I, 2015
  • Virobay Inc. - Phase 0, 2015
  • Virobay Inc. - Preclinical, 2015
  • Virobay Inc. - Discovery, 2015
  • Virobay Inc. - Pipeline by Target, 2015
  • Virobay Inc. - Pipeline by Route of Administration, 2015
  • Virobay Inc. - Pipeline by Molecule Type, 2015
  • Virobay Inc. - Pipeline Products by Mechanism of Action, 2015
  • Virobay Inc. - Recent Pipeline Updates, 2015
  • Virobay Inc. - Dormant Developmental Projects,2015
  • Virobay Inc., Other Locations

List of Figures

  • Virobay Inc. - Pipeline by Top 10 Indication, 2015
  • Virobay Inc. - Pipeline by Stage of Development, 2015
  • Virobay Inc. - Monotherapy Products in Pipeline, 2015
  • Virobay Inc. - Out-Licensed Products in Pipeline, 2015
  • Virobay Inc. - Pipeline by Top 10 Target, 2015
  • Virobay Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Virobay Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Virobay Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top